Amylyx Pharmaceuticals Appoints Erin Whitney Head of Global Clinical Operations, Shauna Horvath Head of Global Marketing and Keith White Head of Global Market Access

  • Amylyx Continues to Expand Leadership Team to Support Clinical Development and Commercial Growth

CAMBRIDGE, Mass.–(BUSINESS WIRE)–
Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS), Alzheimer’s Disease and other neurodegenerative diseases, today announced the appointments of Erin Whitney to Head of Global Clinical Operations, Shauna Horvath, previously a brand strategy consultant to Amylyx, to Head of Global Marketing and Keith White to Head of Global Market Access. These key additions to the Amylyx team are integral to support the company’s continued growth and future commercialization plans.

“We are thrilled to have these highly skilled leaders join the Amylyx team at this critical time of growth as we continue our efforts to advance the development of AMX0035, our investigational product, in multiple neurodegenerative diseases,” said Joshua Cohen, Co-CEO, Chairman and Co-Founder of Amylyx.

“Erin’s deep experience in complex clinical trials, Shauna’s successes in global product launch strategies and Keith’s leadership in working with insurers and health care professionals to provide access to critical orphan therapies will collectively contribute to our efforts to deliver treatments to patients as quickly as possible,” said Justin Klee, Co-CEO and Co-Founder of Amylyx.

Erin Whitney is a highly experienced industry veteran with more than twenty years in clinical research, primarily in the rare disease space. Erin most recently comes from bluebird bio, where she was one of the company’s first clinical operations hires. She helped build bluebird bio’s clinical team and most recently served as Director of Clinical Development Operations for their Sickle Cell Disease Program. Erin succeeded in promoting cross-functional team communication to develop innovative strategies and drove a high-profile, global, multi-center phase III development plan in preparation for MAA and BLA filings. Erin’s passion for the rare disease space was first ignited in her role at Genzyme in 2010, where she helped drive the Pompe Disease Program and saw first-hand how her work directly impacted patients who desperately needed treatment options.

“I am looking forward to collaborating with the Amylyx leadership team and scientists to advance Amylyx’ pipeline utilizing innovative clinical development strategies,” said Erin Whitney. “I believe my experience with building out and advancing clinical programs will help lead AMX0035 through the clinical development process expeditiously. It’s exciting to transition to a company where I have the opportunity to implement my knowledge in the rare disease space and make a lasting impact on patients suffering from neurodegenerative diseases.”

Amylyx has appointed Shauna Horvath as the Head of Global Marketing, who was brought on in 2019 as a consultant. She will lead the company’s intended commercial launch of its first product, AMX0035, for ALS as well as follow-on indications, in the US and across major global markets where approved, including Europe, Canada, Japan, and other regions. Shauna brings extensive experience in global communications, brand planning, product management, and launch excellence. She has held leadership roles at leading global healthcare marketing communications agencies, including Cambridge BioMarketing, with a track record of success for therapeutics for rare and orphan conditions. Shauna was most recently the Founder and Lead Consultant at Synapsis Commercial Strategy, LLC.

“Working with Amylyx over the past year, I’ve been amazed by the company’s relentless drive to help patients and caregivers suffering from the effects of neurodegenerative diseases, such as ALS and Alzheimer’s disease,” said Shauna Horvath. “I am excited to join Amylyx full time to continue to execute global marketing initiatives and help communicate their mission and values to patients, advocates, clinicians and others within the neurodegenerative disease communities.”

Additionally, Keith White joins Amylyx as Head of Global Market Access. With over 20 years of industry experience in commercial and market access, Keith brings a successful track record of developing and executing numerous specialty orphan launches. Keith started his career in sales at Merck, then spent 14 years at Genentech where he held leadership roles in sales, marketing, government affairs and market access. Keith then went on to head up the market access functions at Thrombogenics, Intermune and Intercept Pharmaceuticals. Most recently, Keith served as Vice President, Global Market Access and Pricing at Corbus Pharmaceuticals where he helped construct the global market access and pricing plans in preparation to launch Lenabasum.

“I am excited to begin this new chapter and work with this passionate, experienced team to lead market access for the intended launch of AMX0035. If this investigational product is ultimately approved for ALS, we will work closely with payers and countries to ensure appropriate access and coverage for ALS patients,” said Keith White.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and other neurodegenerative diseases. For more information, visit www.amylyx.com and follow us on LinkedIn and Twitter.


Media:


Merissa Muller

Finn Partners

(617) 778-6633

Merissa.Muller@finnpartners.com

Source: Amylyx Pharmaceuticals, Inc.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.